Share price: 163.00p

Director appointment

12th October 2016

Cello Group plc (AIM: CLL; “Cello”, “The Group”), the healthcare focused strategic marketing group, is pleased to announce the appointment of Chris Jones as Non-Executive Director, effective as of October 17th 2016.

After graduating from Cambridge University, Chris spent 24 years in the advertising industry, ultimately becoming the Global Chairman and Chief Executive Officer of J Walter Thompson Co based in New York, part of WPP Group plc. Since moving back to England in 2002, Chris has held senior positions at companies in the healthcare, financial services, not-for-profit and technology industries. These include Board positions at the large quoted US clinical devices business Becton Dickinson and Co, Xenogen Inc, Freedom Holdings, Richmond Group, and Commarco.

Mark Scott, Chief Executive, commented: “We are delighted to have Chris onboard. He brings with him first-hand experience of growing global professional service businesses, as well as a deep knowledge of the healthcare sector in the US. His participation will be very helpful as we seek to expand Cello’s footprint in the US as part of a more ambitious growth path. “

Other than that set out below, there are no other matters that are required to be disclosed under Schedule 2 paragraph (g) of the AIM Rules in relation to the appointment of Chris Jones.

Current and previous directorships:


Current directorships

Directorships within the last five years

Becton Dickinson & Co

Richmond Group

Results International LLP

Freedom Holdings

 12 October 2016



Cello Group

020 7812 8460

Mark Scott, Chief Executive

Mark Bentley, Finance Director

Cenkos Securities

0207 397 8900

Bobbie Hilliam

Harry Pardoe

 This information is provided by RNS

The company news service from the London Stock Exchange

Contact Us


Cello Health plc

Queens House

8-9 Queen Street



Registered Office

Queens House

8-9 Queen Street



Company Registered

in England no.05120150